The innervation of the human airways is based predominantly on the cholinergic parasympathetic system, and consequently, the tone of the airways is predominantly controlled by the vagus nerve. The nerve releases acetylcholine, which in turn activates muscarinic receptors on smooth muscle and submucosal gland cells, resulting in bronchoconstriction and mucus secretion, respectively. 29 There are 5 types of muscarinic receptors (M1-M5), of which 4 (M1-M4) are active and expressed in the majority of airway cells and lung tissue. 30, 31 In humans, the M1 receptors are located in the periphery of the lungs and airway nodes, whereas the M2 and M3 receptors are located more centrally in the airways and lungs. 29, 30 In human lungs, acetylcholine-induced bronchoconstriction results from the stimulation of M3 receptors on smooth muscle cells. 32 The prolonged pharmacologic activity of tiotropium bromide is the result of its slow dissociation from M1 receptors (expressed particularly in the small airways and believed to facilitate cholinergic traffic through peribronchial ganglia) and M3 receptors (which promote smooth muscle constriction in the airways and increased mucous secretion) and quick dissociation from M2 receptors (which inhibit the further release of acetylcholine from postganglionic nerves and are believed to inhibit smooth muscle relaxation). 29, 30, 32, 33 In asthma, the dysfunction of airway muscarinic receptors has been related to airway hyperresponsiveness, particularly to neuronal M2 receptors, which are susceptible to products released from eosinophils and to viral infection. 26, 33, 34 The mechanism of action of anticholinergic bronchodilators either in asthma or COPD is believed to be related to a reduction in the basal level of bronchomotor tone in the small airways. However, the extent to which the cholinergic tone contributes to the narrowing of the airways in asthma is unclear. 35 Nevertheless, the fact that airway hyperresponsiveness can persist in asthmatic patients, even in the absence of airway inflammation following the long-term use of an ICS, 36 suggests that other factors, such as increased cholinergic and smooth muscle tone, have a role in asthma. 37 Also, there is increasing evidence that cells outside the cholinergic neuronal network, such as airway epithelial cells, synthesize, contain, and release acetylcholine. 28, 38 Thus, acetylcholine is both a neurotransmitter and a local signaling molecule produced by nonneuronal cells. Regardless of the mechanism, the raised parasympathetic tone 39 is sufficient to provide a rationale for the use of tiotropium in asthma.
Clinical insights from tiotropium trials in asthma Despite current effective treatments, suboptimal control of asthma occurs in at least 40% of patients. 40, 41 The current guidelines 4 recommend stepwise management to obtain and maintain control, in which the clinical definition of control is the absence of daytime symptoms or their presence less than twice a week, no need for reliever suboptimal in many patients, especially in those with more severe asthma. 5 Poor adherence, incorrect use of inhaler devices, misdiagnosis, occupational or environmental exposures, and comorbidities may account for a great part of inadequate asthma control.
In a stepwise manner, the Global Initiative for Asthma 4 recommends starting with short-acting β 2 -agonists, quickly followed by inhaled corticosteroids (ICSs) in patients with symptoms occurring every week or more often. However, if the disease remains uncontrolled even after correcting for all the above factors and optimizing asthma treatment at least with an ICS, a step-up in treatment is required.
6 This step-up routinely consists of long-acting β 2 -agonists (LABAs), but control remains poor in many patients. Moreover, some patients cannot tolerate LABAs.
An alternative mode of bronchodilation is antagonizing the cholinergic system. In asthma, the use of short-acting anticholinergics is advocated for exacerbations of asthma in the hospital, but administering these drugs in stable asthma is not generally advocated. 4 It is notable that tiotropium, a potent long-acting selective anticholinergic bronchodilator, approved for use in chronic obstructive pulmonary disease (COPD) for more than a decade, only recently has been investigated as a controller treatment in asthma.
14-24 The role of tiotropium in asthma management has generated great interest as shown by the recent publication of 1 systematic review 7 and 6 meta-analyses. [8] [9] [10] [11] [12] [13] This interest is not unforeseen, as most of the studies investigating the effect of adding tiotropium to asthma treatment were conducted in patients with moderate 14 -16,18-22 and with severe asthma, 23, 24 those with the greatest burden of asthma, significant impact on the quality of life, 25 and those that would benefit most from alternative or additional treatments. This review will critically evaluate the documented evidence of the clinical trials conducted to date and will subsequently assess the therapeutic implications of anticholinergic drugs in the treatment of asthma.
Tiotropium bromide Long-acting β 2 -bronchodilators in combination with an ICS are the preferred option in the management of asthma when the use of an ICS alone does not allow to achieve sufficient disease control.
4 Short-acting anticholinergics (ipratropium bromide) alone or in combination with a short-acting β 2 -agonist have long been used as a reliever medication in asthma. Tiotropium bromide is a potent long-acting selective inhaled muscar inic antagonist with bronchodilator effect sustained for 24 hours. It is extensively used as mainte nance therapy in moderate--to-severe COPD. 26 These bronchodilatory properties, the putative additional effects of tiotropium decreasing mucus production 26 and possibly modulating airway inflammation, 27,28 make this an attractive therapeutic option for the management of asthma. improvement achieved with salmeterol and was superior to placebo. Improvements in symptoms were comparable between tiotropium and salmeterol and better than placebo. In addition, the results suggested that tiotropium might be an alternative add-on treatment for asthmatics with the B16-Arg/Arg genotype requiring treatment with an ICS plus a second controller drug to achieve and maintain asthma control.
Two phase II studies 18, 19 investigated the effect of different doses of tiotropium on symptomatic asthma despite medium doses of ICS alone or associated with a second controller drug. In a doseranging, double-blind, placebo-controlled crossover study published by Beeh et al, 18 174 adults with moderate asthma not fully controlled on an ICS alone (budesonide, 400-800 μg/d, or equivalent) or in a fixed-dose combination with a LABA or short-acting β 2 -agonist were randomized to receive tiotropium delivered via a Respimat inhaler (5, 2.5, or 1.25 μg once daily) or placebo, while discontinuing the LABA medication. Peak FEV 1 , the primary endpoint, was significantly higher with a dose of 5 μg when compared with placebo (by 188 ml), and to 2.5 μg (60 ml), and to 1.125 μg (49 ml). Tiotropium respimat (5 μg) was found to be the most effective and consistent dose, with a safety profile comparable to that of placebo. The second dose-ranging phase II study was published by Vogelberg et al. 19 This study differed from the one performed by Beeh et al 18 by including only adolescents aged from 12 to 17 years and by an incomplete crossover design. Tiotropium respimat (5 μg) was the only dose that was significantly better than placebo in both peak and trough FEV 1 . There were no safety issues. However, the above studies 15, 18, 19 were relatively small. Recently, Kerstjens et al 21 published the results of the first large trials in adults with moderate symptomatic asthma (N = 2103). This consisted of 2 replicate randomized, double-blind, placebo-controlled, parallel-group studies, with an active comparator and 24-week follow-up. Eligible patients were aged from 18 to 75 years with symptomatic asthma and a prebronchodilator FEV 1 of 60% to 90% predicted despite the use of a medium dose of an ICS. They were nonsmokers or ex-smokers for 1 year or more with 10 pack--years or less. Patients randomly received tiotropium (5 μg or 2.5 μg once daily), salmeterol (50 μg twice daily), or placebo, while maintaining ICSs. Primary endpoints were peak and trough FEV 1 , and asthma control assessed as ACQ responder rates. Once-daily tiotropium as add-on treatment to a medium-dose ICS resulted in significant improvements in lung function and asthma control compared with placebo, and which were similar to those recorded for twice-daily salmeterol. There was no significant difference between the 2 doses of tiotropium. In addition, the safety of tiotropium was similar to that of salmeterol.
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Tiotropium in severe asthma The role of tiotropium in severe asthma was examined in 3 clinical medication or less than twice a week, no limitations of activity, and no nocturnal awakenings from asthma symptoms.
Tiotropium has been investigated in mild-to--moderate and in severe asthma, which will be discussed separately.
Tiotropium in mild-to-moderate asthma The role of tiotropium in mild-to-moderate asthma or in moderate asthma has been investigated in various randomized, double-blind, placebo-controlled clinical trials (RCTs) [15] [16] [17] [18] [19] [20] [21] [22] with a duration that ranged from 4 to 52 weeks (TABLE 1) , and reviewed in a recent meta-analysis. 13 The TALC trial 16 was the only published study to investigate the role of tiotropium in mild-to-moderate asthma, though an additional trial has been presented as an abstract. 17 In the other studies, [15] [16] [17] [18] [19] the severity of asthma was moderate. The primary outcome was morning peak expiratory flow (PEF) in 2 studies, 15, 16 peak forced expiratory volume in 1 second (FEV 1 ) in 2 studies, 17, 18 and peak FEV 1 area under the curve from zero to 24 hours in 1 study. 19 In another manuscript, which comprised of 2 replicate RCTs, prespecified coprimary endpoints were peak and trough FEV 1 and asthma control.
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In the investigator-initiated TALC trial (tiotropium as an alternative to increase the dose of an ICS in patients inadequately controlled on a lower dose of an ICS), a 3-way randomized, double--blind, triple-dummy crossover study of 14 weeks of duration, 210 subjects were included and 174 completed all the study arms. 15 The primary outcome measure was the morning PEF and secondary outcomes included prebronchodilator FEV 1 , the number of asthma-control days (defined as days without symptoms and without the use of a rescue bronchodilator), asthma symptoms, the Asthma Control Questionnaire (ACQ), 42 and the Asthma Quality-of-Life Questionnaire (AQLQ), 43 among others. This is the only study in this review performed with the dry-powder formulation of tiotropium. It demonstrated that treatment with tiotropium (18 μg) via HandiHaler plus beclomethasone (2 puffs of 40 μg twice daily) resulted in greater improvements in PEF compared with doubling the dose of an ICS (160 μg, 2 puffs of 80 μg twice daily of beclomethasone) and similar to adding salmeterol (50 μg) twice daily. Also, treatment with added tiotropium was associated with improvements in spirometry, asthma control, and provided symptomatic benefit that was greater than doubling the dose of an ICS, and either noninferior to or better than salmeterol.
In another study, with a similar design, Bateman et al, 16 based on the concerns regarding the safety of LABAs in asthmatic patients with the B16-Arg/Arg genotype, investigated the role of tiotropium as add-on treatment in patients with this genotype and moderate asthma not controlled by an ICS alone (budesonide, 400-1000 μg/d, or equivalent). This study provided evidence that tiotropium (5 μg) was not inferior to salmeterol treatment in maintaining the lung function a ex-smokers: individuals who had stopped smoking ≥1 years prior to enrollment and with a smoking history of <10 pack-years All studies used a tiotropium respimat inhaler unless otherwise specified.
Abbreviations: ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality-of-Life Questionnaire; BD, bronchodilator, BUD, budesonide; DB, double--blind; FEV 1 , forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABA, long-acting β 2 -bronchodilator; OD, once daily; PC, placebo-controlled; PEF, peak expiratory flow; TIO, tiotropium; SALM, salmeterol; RCT, randomized controlled trial was added to a high-dose ICS plus LABA in severe asthmatics followed for 48 weeks, 24 among the adverse events reported by at least 2% of the patients in any study group, only allergic rhinitis occurred at a significantly higher rate in the tiotropium group, and asthma events and insomnia were significantly more common in the placebo group. Again, the incidence of cardiac adverse events was less than 2%, with no difference in occurrence between the active or placebo treatment groups. [21] [22] [23] [24] In the only study that examined tiotropium at a dose of 5 μg or 10 μg as add-on therapy to an ICS plus LABA in severe asthma, adverse events were slightly higher in subjects receiving tiotropium at a dose of 10 μg (50% vs 40% in subjects on tiotropium at a dose of 5 μg and 42% in subjects on placebo).
In a longer study, Otha et al 22 examined the tolerability profile of tiotropium as an add-on therapy in patients from Japan who had moderate--to-severe symptomatic asthma while receiving a medium-dose ICS, with or without a LABA. The safety profile of tiotropium was similar to that in previous studies. 21, 24 Over 52 weeks, adverse events were generally mild and nonserious, and the overall tolerability profile of tiotropium was comparable to that of placebo.
Discussion Taken together, the results of the 10 published RCTs 15-24 demonstrated that: 1) adding tiotropium at a dose of 5 μg in patients with symptomatic asthma despite low-to-high doses of an ICS with or without LABA significantly improves FEV 1 compared with placebo; 2) adding tiotropium at a dose of 5 μg in patients with symptomatic asthma despite high-doses of an ICS and LABA significantly lengthens the time to the first severe exacerbation 24 ; 3) adding tiotropium at doses of 2.5 μg and 5 μg once daily to a medium--dose ICS significantly increases asthma control expressed as ACQ responders when compared with placebo 21 ; 4) adding tiotropium at a dose of 5 μg once daily to an ICS is at least comparable to adding salmeterol 15 (TABLE 2) . In a relatively small phase II trial (n = 107), Kerstjens et al 23 compared the efficacy and safety of 2 doses of tiotropium (5 μg 10 μg daily) with placebo as add-on therapy in patients with uncontrolled severe asthma as measured by an ACQ score of 1.5 or higher while on a combination of a high-dose ICS and LABA. Adding tiotropium at a dose of 5 μg or 10 μg daily resulted in an improvement in peak FEV 1 of 139 ml and 170 ml, respectively. Morning and evening PEF was slightly but significantly higher with a dose of 10 μg compared with that of 5 μg.
The second published manuscript on severe asthma 24 reported on 2 replicate RCTs involving 912 asthmatics who were receiving a high--dose ICS plus LABA. This study compared the effect of adding tiotropium (5 μg) or placebo on lung function and exacerbations, both delivered by a Respimat inhaler once daily for 48 weeks. The improvements in peak FEV 1 were 86 ml and 154 ml in trials 1 and 2, respectively, compared with placebo, and the improvements in trough FEV 1 were 88 ml and 111 ml in trials 1 and 2, respectively, compared with placebo (all P ≤0.01). Also, the addition of tiotropium significantly increased the time to the first severe exacerbation (282 days vs 226 days), with an overall reduction of 21% in the risk of a severe exacerbation. Adverse events were similar in both groups.
Safety of tiotropium in asthma
The safety of tiotropium as add-on treatment was examined in 3705 patients, 18, 19, [21] [22] [23] [24] either when added to a medium-dose ICS for 24 to 52 weeks 18, 19, 21, 22 or to a high-dose ICS plus LABA for 48 weeks.
23,24
In 2 large trials with tiotropium added to a medium-dose ICS, 21 the numbers of adverse events were very similar between tiotropium at doses of 2.5 μg or 5 μg, salmeterol, and placebo. Especially cardiac adverse events were recorded in less than 2% of all patients, with no differences between the treatment groups. Dry mouth was recorded in less than 2% of subjects in any treatment group. In 2 other large trials, in which tiotropium characteristics: disease duration, age class, smoking, history, sex, percent predicted prebronchodilator FEV 1 at baseline, allergic status (assessed by the concentration of immunoglobulin E [IgE], eosinophil count, or clinical judgment), region, and body-mass-index class. 21, 23 This renders the addition of tiotropium at a dose of 5 μg a valuable option in a broad group of patients with symptomatic asthma while being treated by an ICS with or without LABA, and averts the need for biomarker testing before the start of treatment such as with anti-IgE or anti-interleukin-5.
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EP has received consultancy fees from Novartis, Boehring Ingelheim, GlaxoSmithKline, AstraZeneca, Takeda, and Chiesi and has received lecture fees from Novartis, Boehring Ingelheim, GlaxoSmithKline, Chiesi, AstraZeneca, and Ache. low--to-medium dose of an ICS; and 5) adding tiotropium at a dose of 5 μg once daily either to an ICS alone or to ICS plus LABA in these studies has a favorable safety profile similar to that of salmeterol and placebo. 21, 23 Rodrigo et al 13 have recently assessed that the major benefits of adding tiotropium were improvements in lung function and, in patients with severe asthma, the reduction of exacerbations. They calculated a reduction of 30% in asthma exacerbations with a number needed to treat of 17. These results are relevant because of the great impact of exacerbations of severe asthma and the costs of current alternatives to reduce asthma exacerbations in this particular group of asthmatics.
Furthermore, Price et al 44 examined the clinical effects of add-on therapy with tiotropium in a real-life study of a group of over 2042 asthma patients treated in primary care practice in the United Kingdom. The study patients were at least 18 years of age and had a physician-recorded diagnosis of asthma and the only exclusion criteria was a recorded diagnosis of COPD. In this study, the addition of tiotropium was associated with significant decreases in the incidence of exacerbations within the first year of treatment.
It would be useful for clinicians to predict which patients respond to tiotropium and which do not. Interestingly, none of the published studies has been able to discriminate responders from nonresponders to tiotropium respimat. Subgroup analyses showed no overall differences in improvement in lung function by the following baseline 
